Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dihydrotanshinone I is a bioactive lipophilic abietane diterpenoid isolated from the root of *Salvia miltiorrhiza* (Danshen), a staple of traditional Chinese medicine. It exhibits significant antineoplastic, anti-inflammatory, and cardiovascular protective properties. In oncology research, dihydrotanshinone I has demonstrated the ability to induce apoptosis in various cancer cell lines, including glioblastoma, by promoting the generation of reactive oxygen species (ROS) and inducing endoplasmic reticulum (ER) stress. It is particularly noted for its potential as a chemosensitizer; it can cross the blood-brain barrier and downregulate the expression of O6-methylguanine DNA methyltransferase (MGMT) and P-glycoprotein (P-gp), thereby enhancing the efficacy of chemotherapeutic agents like temozolomide. Furthermore, it modulates several key signaling pathways, including the inhibition of NF-κB and the PI3K/AKT pathway, to suppress tumor cell proliferation and survival.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dihydrotanshinone I.